Data Gumbo CEO discusses Houston's startup ecosystem and goals for his company

Featured innovator

Andrew Bruce had the idea for Data Gumbo when he realized how difficult it was to share data in upstream oil and gas. Courtesy of Data Gumbo

For Andrew Bruce, an oil and gas professional and entrepreneur, there's nothing like Houston.

"I've lived in Boston, New York, and London, and I've spent a lot of time in Norway," Bruce says. "They are all wonderful places, but I've never experienced anything quite like Houston."

After a long career in oil and gas, Bruce found himself a victim of the oil downturn. Once laid off, he decided to focus on a new idea for a way to provide access to upstream oil and gas data to companies. He founded Data Gumbo Corp., a blockchain-as-a-service company based in Houston, in 2016. The company closed its seed round last year and is moving toward a series A.

While Bruce credits his trajectory from laid off to startup CEO to a lot of hard work and a bit of blind luck, he says that Houston's people and the help they are willing to provide has been extremely beneficial to the growth of Data Gumbo.

"I'm just brainstorming, but I think a lot of [what makes Houston great for startups] comes from the fact that we all recognize the cyclical nature of the oil and gas industry, we are obligated to look out for each other even when people are laid off," Bruce says. "Maybe it comes from that kind of recognition that we're all in this together and we have to try to work through it."

InnovationMap: Tell me a little bit about your background.

Andrew Bruce: Started out as a programmer, and was transferred from New York City to Houston to build a consulting practice for financial systems. My background originally in London was building systems for the deregulation of banking industry that was happening in the mid 80s.

When I came to houston, I got involved in energy trading systems. I built a small software startup, and eventually got involved in National Oilwell Varco and the drilling business. As part of that, I kicked off a program called NOVOS to build an autonomous drilling rig. Came across the challenge of not having access to data for that rig. Data Gumbo was a direct result of that.

I started Data Gumbo to solve the problem of not being able to get data from industrial installations. Along the way, I came across the opportunity for blockchain because the real problem people were trying to solve was mistrust and inefficiency of the process. I stumbled into blockchain kind of backwards.

IM: How does Data Gumbo work?

AB: The whole idea is to build out the blockchain network, and provide a network that they can subscribe to and start doing business on that network. It's a service, so there's a subscription fee. It gives them access to the savings they already have available within their organizations.

IM: Who are the type of customers you're looking for?

AB: Midstream and upstream oil and gas companies, and the service companies that serve them.

IM: What was the reception like at first?

AB: Difficult. We got a lot of questions and concerns about what blockchain is, why they need it, and whether or not they can trust it. We were introducing a completely new concept to a conservative industry.

IM: What were some challenges and opportunities?

AB: No. 1 is the Operators Blockchain Consortium, which was 19 different oil companies coming together to understand blockchain and its opportunities. That's helped. And 75 percent of our early calls were sort of evangelism of explaining blockchain and how it's different from cryptocurrency. So, it was an educational process. The industry was independently going down the road of understanding the technology. And, to be perfectly honest, it was a bit of blind luck that we chose this technology that the industry was getting behind anyways.

IM: What doors does your recently closed seed round open?

AB: Now we're pursuing a series A equity round. Seed was a bridge to equity funding. It was primarily individuals in town who got behind the company and believed in what we were trying to do. They helped open some doors, but primarily it was financing to get us to series A and prove the concepts from a sales and product market fit perspective.

IM: What are you long-term goals for Data Gumbo?

AB: To take the company public and to remain independent. We believe that we want to provide a service to the customers that is independent from any other offers. We want to stay true to our roots and be a blockchain network infrastructure people can trust and rely on for not just upstream oil and gas, but also getting into trucking and shipping and other adjacent industries so we can satisfy the whole supply chain.

IM: How is it being located in Houston?

AB: Houston's startup community has been amazing. When we started this journey, it had been a while since we had any entrepreneurial contacts, so it was basically like starting from scratch. Organizations like Station Houston and, later on, The Cannon helped provided great contacts. People from those organizations — and the business community as a whole — has been really generous with their time. Houston is probably second to none when it comes to people's willingness to help.

IM: What does Houston still need to work on as an innovation ecosystem?

AB: I don't think it's Houston specifically, but a generalization is that large corporations are set up to buy from large corporations. As a small company or startup to sell to a super major is difficult because the sales cycle is so long and the requirements are set up to buy from other large companies. If there was a way for creating an entrepreneurial division of these companies so that they can experiment with and support startups, that would be tremendous. If you're a startup, you should be focused on sales, but cracking that nut within a large company is really hard.

IM: What keeps you up at night as it pertains to business?

AB: People. I've viewed my roles with a huge responsibility. There are people who make a bet on a company, whether they be investors or employees, and you've got to be able to fund the company. So, whether it be through sales revenue or fundraising, making payroll and building a company that people can get a return on their investment is a huge responsibility. So, that's what keeps me up at night — making sure that I'm repaying people's faith in what we're doing.

------

Portions of this interview have been edited.

Christopher Robart leads Ambyint — a technology company creating the Nest thermostat for oil rigs — with his twin brother, Alex. Courtesy of Ambyint

Oil and gas startup exec positions Houston company for more growth in 2019

Featured Innovator

Most of Christopher Robart's 10-year career in oil and gas has been deliberate and calculated — researching the right startup to be involved in or finding the right buyer for a company he invested in. However, his actual start in the industry wasn't so intentional.

"I sort of fell into oil and gas after I got of college back in 2003," says Robart, who is the president of Ambyint USA. "Before that, I was involved in a few startup things — some digital and some not. I was always sort of an entrepreneur."

Robart shares the passion of entrepreneurialism with his twin brother, Alex, CEO of Ambyint. The two have similar work experiences, since they act as an oil and gas startup team in Houston. One of the first companies the duo bought and sold was PacWest Consulting Partners, which was sold to IHS Energy in 2014, Robart says. The second one, Digital H2O, they founded, grew the team, lead some investments, and sold it to Genscape in 2015.

The pair's newest endeavor is Ambyint, an oilfield smart technology company with Canadian origins. The Robart brothers have been involved in it for about two and a half years.

Christopher Robart spoke with InnovationMap about his career and what he hopes to accomplish with his oil and gas startup in 2019.

InnovationMap: How did you and your brother first get involved in Ambyint?

Christopher Robart: After we left IHS, we knew that our next up was going to be software and upstream oil and gas, but there were a lot of question marks. We did our due diligence. We leveraged all that information we found and settled on which market we wanted to be in. We ended up finding Ambyint and liked what they had built to date, but they had some gaps and shortcomings, particularly on the commercial side, and they had no U.S. presence. We thought those two gaps were something we'd be helpful filling out. We went through a fairly lengthy process to lead an investment into the company, and essentially took over through that process.

IM: So, Ambyint still has an office in Canada?

CR: The Canada office is primarily a technology office, with some sales capabilities up there. The U.S. is primarily sales, marketing, and customer support.

IM: How does the technology work?

CR: The easiest way to explain it is we're like a Nest thermostat for your oil wells. It's a piece of hardware and a piece of software. It's wired into the well's control system and tied up to cloud-based software. From there, we've been deploying artificial intelligence, machine learning, deep learning, etc.

IM: What do you look for in customers?

CR: Oil companies of any shape or size, really. Oil and gas industry aren't really known for being early adopters of technology. There's a lot of resistance to change, particularly at the production level, which we focus on. So we're looking for early adopters looking to lead the way.

We're in pretty much all the major oil-producing areas in the U.S. and Canada. We also have customers in Mexico, Chili, and Egypt. There's a few more countries in the Middle East we're trying to get into.

IM: Are you planning another fundraising round?

CR: We'll embark on a series B in the near future. We closed our series A, and it was pretty large, so we're in a good place. (The series closed in September of 2017 with $11.5 million raised, according to Crunchbase.)

IM: What are your goals for 2019?

CR: We've built a lot of cool technology, and we continue to do that. Our focus for 2019 is to continue to commercialize and expand our customer base. Our sales cycle is pretty long. It could be a year from the time we bring an initial lead to the table, running a pilot, getting results, and developing a plan. It's a long, slow, and, in some cases, a painful process.

When you're doing things like machine learning, you're teaching a machine how to do something a human would do something. What's required to do that is a massive amount of data to start, and from there, it's a never ending journey of data collection and monitoring your accuracy.

We've been focused on one specific artificial lift pump — every well will eventually take a piece of artificial lift pump. We work on the most common artificial lift pump, but it's just one of six key types. In addition to selling more of that pump, we are in the process of expanding to additional lift types.

IM: What keeps you up at night, as it pertains to your business?

CR: Change management. Getting our customers to adopt new technology and embrace change. That's it. We're constantly trying to get our customers to move more quickly.

IM: How do you and your brother work together? Do you each play different roles in the company?

CR: Our backgrounds are similar. We're twins, but we have personality differences. I spend a little more time with our customers than he does and with new product initiatives. I get pretty hands on.

His mandate is less focused on walking and talking with customers and more on managing the functions of the business and working with the leadership team. As well as financing and fundraising.

We've got a pretty good division of labor, but there is a lot of overlap of what we do.

IM: What are some of the pros and cons of being in Houston?

CR: Obviously the pro of being in Houston is it being the oil capital of the world. All our customers are here. It's sort of a must.

The downside of running a technology company in town is that tech talent is quite thin on the ground in Houston — especially what we're looking for. So, we don't have any tech team members in the Houston office. I'll put it mildly in that we are skeptical of the talent pool for really strong software developers in the Houston market.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings